Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.
作者信息
Nastoupil Loretta J, Flowers Christopher R
机构信息
Winship Cancer Institute, Emory University, Atlanta, GA.
出版信息
Community Oncol. 2012 Dec;9(12):S85-S92. doi: 10.1016/j.cmonc.2012.09.019.
Abstract
摘要
相似文献
1
Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice.复发性慢性淋巴细胞白血病的管理：将指南应用于实践
Community Oncol. 2012 Dec;9(12):S85-S92. doi: 10.1016/j.cmonc.2012.09.019.
2
Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.癌症特异性应激与复发性/难治性慢性淋巴细胞白血病患者心理和生理功能的变化轨迹。
Ann Behav Med. 2018 Mar 15;52(4):287-298. doi: 10.1093/abm/kax004.
3
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.加拿大复发/难治性慢性淋巴细胞白血病治疗的循证指南。
Leuk Res. 2023 Oct;133:107372. doi: 10.1016/j.leukres.2023.107372. Epub 2023 Aug 19.
4
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.靶向治疗时代复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的管理
Curr Hematol Malig Rep. 2022 Feb;17(1):39-45. doi: 10.1007/s11899-021-00652-2. Epub 2022 Jan 13.
5
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.HELIOS试验方案：一项关于伊布替尼联合苯达莫司汀和利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的III期研究。
Future Oncol. 2015;11(1):51-9. doi: 10.2217/fon.14.119.
6
Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience.开发慢性淋巴细胞白血病概念模型以更好地了解患者体验。
Patient. 2021 Jan;14(1):75-87. doi: 10.1007/s40271-020-00440-9.
7
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
8
Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.慢性淋巴细胞白血病/小淋巴细胞白血病管理的长期随访和未来方向。
J Oncol Pharm Pract. 2022 Dec;28(8):1869-1884. doi: 10.1177/10781552221103820. Epub 2022 May 30.
9
Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.扩大慢性淋巴细胞白血病的治疗手段：慢性淋巴细胞白血病治疗中新型药物的综述
J Oncol Pharm Pract. 2017 Oct;23(7):502-517. doi: 10.1177/1078155216656929. Epub 2016 Jun 29.
10
Oral oncolytic treatment for chronic lymphocytic leukemia.慢性淋巴细胞白血病的口服溶瘤治疗
J Oncol Pharm Pract. 2022 Jun;28(4):935-944. doi: 10.1177/10781552211073906. Epub 2022 Jan 27.
引用本文的文献
1
Deceased donor kidney transplantation in candidates with pre-transplant hematological malignancies: a literature review and recipient allocation proposal in Singapore.移植前存在血液系统恶性肿瘤的候选者接受 deceased donor 肾脏移植：新加坡的文献综述及受者分配建议
J Nephrol. 2025 Aug 22. doi: 10.1007/s40620-025-02381-8.
2
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.RESONATE 期 3 试验伊布替尼与奥法妥木单抗的长期随访。
Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.
3
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.解析慢性淋巴细胞白血病的分子格局：疾病演变的时间框架
Haematologica. 2015 Jan;100(1):7-16. doi: 10.3324/haematol.2014.115923.
本文引用的文献
1
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.赖·KR、萨维茨基·A、克朗凯特·EP、查纳纳·AD、利维·RN、帕斯特纳克·BS。慢性淋巴细胞白血病的临床分期。《血液》。1975年；46(2):219 - 234。
Blood. 2016 Oct 27;128(17):2109. doi: 10.1182/blood-2016-08-737650.
2
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.微小残留病灶定量是慢性淋巴细胞白血病无进展和总生存的独立预测因子：来自随机 GCLLSG CLL8 试验的多变量分析。
J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.
3
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.Ofatumumab 在既往接受氟达拉滨治疗且对利妥昔单抗耐药的 CLL 患者中具有活性：来自国际 2 期研究的结果。
Blood. 2011 Nov 10;118(19):5126-9. doi: 10.1182/blood-2011-04-348656. Epub 2011 Aug 19.
4
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.苯达莫司汀联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病患者：德国慢性淋巴细胞白血病研究组的一项多中心 II 期试验。
J Clin Oncol. 2011 Sep 10;29(26):3559-66. doi: 10.1200/JCO.2010.33.8061. Epub 2011 Aug 15.
5
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.布鲁顿酪氨酸激酶是治疗慢性淋巴细胞白血病的一个很有前途的治疗靶点，它可以被 PCI-32765 有效靶向。
Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.
6
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.氟达拉滨、环磷酰胺和利妥昔单抗化疗免疫治疗是治疗 CLL 复发患者的非常有效方法。
Blood. 2011 Mar 17;117(11):3016-24. doi: 10.1182/blood-2010-08-304683. Epub 2011 Jan 18.
7
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.CAL-101 是一种 p110delta 选择性磷脂酰肌醇-3-激酶抑制剂，用于治疗 B 细胞恶性肿瘤，可抑制 PI3K 信号和细胞活力。
Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19.
8
Chronic lymphocytic leukemia.慢性淋巴细胞白血病。
Ann Oncol. 2010 Oct;21 Suppl 7:vii154-64. doi: 10.1093/annonc/mdq373.
9
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者的随机、开放标签、3 期临床试验。
Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
10
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.LRF CLL4 试验确定了预后因素，将患者分为三个风险组，与治疗分配无关。
Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338. Epub 2010 May 29.
Zotero 插件